J
JURA Bio
Creating a novel therapeutic platform of cell-based therapies against autoimmune diseases
About JURA Bio
JURA Bio, Inc. is pioneering the development of novel CAR T cell therapies aimed at combating autoimmune diseases, which affect over 20 million Americans. Autoimmune diseases occur when the immune system mistakenly attacks the body's own tissues, leading to significant health issues. JURA Bio's innovative therapeutic platform focuses on targeting and neutralizing these pathogenic immune cells, thereby interrupting the damaging cascade of events triggered by the immune system's malfunction.
The company operates in the biopharmaceutical sector, specifically within the niche of cellular medicine. Its primary clients include healthcare providers, research institutions, and potentially patients suffering from autoimmune conditions. JURA Bio's business model revolves around the research, development, and commercialization of its proprietary CAR T cell therapies. Revenue is generated through partnerships, licensing agreements, and eventually, the sale of its therapeutic products once they receive regulatory approval.
JURA Bio's approach is disruptive, leveraging the concept of immune synapses to precisely target and neutralize harmful cells. This method represents a significant advancement in the treatment of autoimmune diseases, offering hope for more effective and targeted therapies.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Sep 2023 | $16M | $64M | Fontus Capital | ↗ |
| SPINOUT✓Other financing | Jan 2017 | $0 | — | Harvard University | — |
Growth signals
Latest recorded traffic for JURA Bio is 890 monthly website visits, up 53.4% over the last three months. JURA Bio's team declined 7.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
JURA Bio in the Somerville ecosystem
The JURA Bio office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
- FCFontus Capital
Other known investors2 additional known investors
Harvard University
Greentown Labs
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about JURA Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See JURA Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










